| 0.495 0 (0%) | 06-12 09:50 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1-year : | ||
| Resists | First : | Second : | ||
| Pivot price | ||||
| Supports | First : | Second : | ||
| MAs | MA(5) : | MA(20) : | ||
| MA(100) : | MA(250) : | |||
| MACD | MACD : | Signal : | ||
| %K %D | K(14,3) : | D(3) : | ||
| RSI | RSI(14): | |||
| 52-week | High : | Low : | ||
| If tomorrow: | Open lower | Open higher |
| High: | - | - |
| Low: | - | - |
| Close: | - | - |
Orgenesis Inc. is a global biotechnology firm dedicated to the field of cell and gene therapies. The company has engineered an innovative Point of Care (POCare) platform. This system incorporates a portfolio of licensed POCare therapeutics, which are manufactured and prepared using automated, self-contained POCare technology within a cooperative network. Orgenesis primarily concentrates on autologous therapies, developing customized processes and systems for each treatment. These utilize a closed, automated processing methodology, validated for safe and compliant production directly at the patient's location, facilitating immediate therapeutic application. Established in 2008 as Business Outsourcing Service, Inc., the company adopted the name Orgenesis Inc. in August 2011 and is headquartered in Germantown, Maryland.
Thu, 21 May 2026
Orgenesis Inc stock (US68621F1021): delisting to OTC puts spotlight on business model and risks - AD HOC NEWS
Thu, 14 May 2026
Orgenesis stock (US68621F1021): Recent clinical trial progress draws investor attention - AD HOC NEWS
Mon, 26 Jan 2026
Orgenesis Signs Warrant Issuance Agreement With Alpha Prosperity Fund - TradingView
Tue, 19 Aug 2025
Orgenesis announces resignation of CFO and three board members - Investing.com
Thu, 17 Oct 2024
Orgenesis Inc. to be delisted from Nasdaq - Investing.com
Tue, 30 May 2023
Claudia Zylberberg Appointed as Independent Board Member of POCare Business Subsidiary of Orgenesis - citybiz
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
OTC
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | (%) |
| Held by Institutions | (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | |
| EPS Est Next Qtrly | |
| EPS Est This Year | |
| EPS Est Next Year | |
| Book Value (p.s.) | |
| Profit Margin | % |
| Operating Margin | % |
| Return on Assets (ttm) | % |
| Return on Equity (ttm) | % |
| Qtrly Rev. Growth | % |
| Gross Profit (p.s.) | |
| Sales Per Share | |
| EBITDA (p.s.) | |
| Qtrly Earnings Growth | % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | |
| PEG Ratio | |
| Price to Book value | |
| Price to Sales | |
| Price to Cash Flow |
| Dividend | |
| Forward Dividend | |
| Dividend Yield | 0% |
| Dividend Pay Date | |
| Ex-Dividend Date |
|
|
|
|
|
|
|
|
|